NVS acquires (private) Selexys Pharmaceutical—a player in SCD: https://globenewswire.com/news-release/2016/11/21/891526/0/en/Novartis-acquires-Selexys-Pharmaceuticals-Corporation-and-SelG1-antibody-for-reduction-of-pain-crises-in-sickle-cell-disease-SCD.html NVS is exercising an exclusive option obtained in 2012; total "biobucks" are $665M, but detailed terms of the deal have not been disclosed.